Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Camrelizumab and Palbociclib in Resectable Esophageal Squamous Cell Carcinoma
NCT06654297Phase 1Active, not recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Oct 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of camrelizumab and palbociclib in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Safety assessed by adverse events at 15 weeks and Feasibility assessed by adverse events at 15 weeks. Started Oct 2024; status: active, not recruiting.
02
Drugs
camrelizumabpalbociclib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06654297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06654297.